Formulary Management of Targeted Immune Modulators in Ulcerative Colitis


 Health Canada has approved 7 targeted immune modulators for the treatment of adults with moderate to severe ulcerative colitis, which include 5 biologics (adalimumab, infliximab, golimumab, ustekinumab, and vedolizumab) 2 small molecules (tofacitinib ozanimod). Biosimilars adalimumab infliximab generics tofacitinib are currently available in Canadian market; however, although their patent protection expired, there no biosimilars golimumab ustekinumab.
 All have undergone pan-Canadian Pharmaceutical Alliance negotiations concluded a Letter Intent except is only modulator not included on any public formularies colitis. Coverage consistent across all drug plans tofacitinib, covered by jurisdictions colitis.
 Most implemented or announced biosimilar policy promote use over originator biologics. The listing status colitis similar plans; heterogeneity criteria requirements prior treatments diagnosis definitions.
 Considering these factors emergence new data, it would be important reassess drugs evaluate place therapy. Further research, such as horizon scanning, utilization analyses, long-term effectiveness safety studies, warranted ensure appropriate